S100A9 and hepatocellular carcinoma: HNRNPL and S100A9 are overexpressed in hepatocellular carcinoma (HCC) and promote ferroptosis resistance; silencing HNRNPL enhances ferroptosis by reducing cellular antioxidants and increasing oxidative stress markers, while S100A9 overexpression or ferroptosis inhibition reverses these effects, suggesting a targetable mechanism for enhancing ferroptosis in HCC therapy.